A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

NCT07668336 on ClinicalTrials.gov · last registry update 2026-09-25

A small phase 3 — 170 participants, against a typical 424. Due to report March 2030, alongside 7 other tracked readouts that quarter. Primary outcome, as filed: Change from Baseline in Hemoglobin A1c (HbA1c). Sponsors move these dates routinely; any movement since this site started watching is listed below. dulaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: NOT_YET_RECRUITING
Phase: P3
Drug: dulaglutide
Trulicity
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 170
Started: 2026-09
Primary completion: 2030-03 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change from Baseline in Hemoglobin A1c (HbA1c)

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.